Drugs / PUR001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05234853 | Apr 2022 → Dec 2023 | cancer | Purinomia Biotech, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PUR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05234853 ↗ |
| Modality | Monoclonal antibody | “an anti-CD39 monoclonal antibody” NCT05234853 ↗ |
| Route | Intravenous | “PUR001 Administered Intravenously” NCT05234853 ↗ |